Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Assessment of predictive values of tumor markers.

Roulston JE.

Methods Mol Med. 2004;97:13-27. Review. No abstract available.

PMID:
15064482
2.

Screening with tumor markers: critical issues.

Roulston JE.

Mol Biotechnol. 2002 Feb;20(2):153-62. Review.

PMID:
11876472
3.

Markers of tumor burden : an overview.

Roulston JE.

Methods Mol Med. 2001;39:109-20. doi: 10.1385/1-59259-071-3:109.

PMID:
21340761
4.

Serum amylase isoenzymes in patients undergoing operation for ruptured and non-ruptured abdominal aortic aneurysm.

Adam DJ, Milne AA, Evans SM, Roulston JE, Lee AJ, Ruckley CV, Bradbury AW.

J Vasc Surg. 1999 Aug;30(2):229-35.

5.

Performance improvement: the organization's quest.

McKinley CO, Parmer DE, Saint-Amand RA, Harbin CB, Roulston JC, Ellis RA, Buchanan JR, Leonard RB.

Qual Manag Health Care. 1999 Winter;7(2):50-9.

PMID:
10346462
6.

Novel tumour markers: a diagnostic role in pancreatic cancer?

Roulston JE.

Br J Cancer. 1994 Sep;70(3):389-90. No abstract available.

7.

Community photoscreening of six to nine month old infants for amblyopiogenic risk factors.

Hope C, Roulston J, Hoey C, Wong A, Clover G.

Aust N Z J Ophthalmol. 1994 Aug;22(3):193-202.

PMID:
7818878
8.

Serological markers for metastatic breast cancer.

Ng JS, Sturgeon CM, Seth J, Paterson GM, Roulston JE, Leonard RC.

Dis Markers. 1993 Dec;11(5-6):217-23.

PMID:
8082311
9.

The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer.

Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RC, Wilkinson P, Cruickshank D, McAllister EJ, Redman CW, Parker D, Scott IV, Slevin ML, Roulston JE.

Int J Gynecol Cancer. 1993 Sep;3(5):285-292.

PMID:
11578359
10.

The effect of surgery on the serum concentration of CA125 in epithelial ovarian cancer.

Beattie GJ, Sturgeon C, Fisken J, Roulston JE.

Ann Clin Biochem. 1993 Jul;30 ( Pt 4):402-3. No abstract available.

PMID:
8379653
11.

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE.

Br J Cancer. 1993 Jul;68(1):140-5.

12.

The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.

Fisken J, Roulston JE, Sturgeon C, Badley RA, Jönrup I, Aspinall L, Leonard RC.

Br J Cancer. 1993 May;67(5):1065-70.

13.

Should we regard CA125 as the indication to treat relapsing ovarian cancer?

Fisken J, Leonard RC, Roulston JE.

Ann Oncol. 1993 Mar;4(3):257. No abstract available.

PMID:
8471561
14.

Alpha-fucosidase as a marker of genetic deletion in ovarian carcinoma.

Beattie GJ, Roulston JE, Eccles DM, Richardson JM, Fisken J, Leonard RC.

Ann Clin Biochem. 1993 Mar;30 ( Pt 2):207-8. No abstract available.

PMID:
8466157
15.

Measurement of placental alkaline phosphatase activity in benign and malignant pleural effusions.

Fergusson RJ, Fisken J, McIntyre MA, Roulston JE, Leonard RC.

J Clin Pathol. 1992 Dec;45(12):1114-5.

16.

Investigation of the c-neu proto-oncogene related protein, p185, in the serum of primary epithelial ovarian cancer patients.

Fisken J, Roulston JE, Beattie G, Hayes DF, Leonard RC.

Int J Gynecol Cancer. 1992 May;2(3):134-140.

PMID:
11576248
17.

Report of BACR workshop on monoclonal antibodies in breast and ovarian cancer, Brasenose College, Oxford March 17-19th 1991.

Leonard RC, Fisken J, Roulston JE.

Br J Cancer. 1991 Oct;64(4):796-7. No abstract available.

18.

Serological monitoring of epithelial ovarian cancer.

Fisken J, Leonard RC, Badley A, Jönrup I, Aspinall L, Sturgeon C, Roulston JE.

Dis Markers. 1991 May-Aug;9(3-4):175-90.

PMID:
1813209
19.

Limitations of tumour markers in screening.

Roulston JE.

Br J Surg. 1990 Sep;77(9):961-2. No abstract available.

PMID:
2095760
20.

Vasopressin secretion in diabetic subjects with and without autonomic neuropathy: responses to osmotic and postural stimulation.

Reid W, Ewing DJ, Lightman SL, Eadington D, Williams TD, Roulston JE, Clarke BF.

Clin Sci (Lond). 1989 Dec;77(6):589-97.

PMID:
2605866
21.
22.

Immunoassay of CA125 in ovarian cancer: a comparison of three assays for use in diagnosis and monitoring.

Fisken J, Leonard RC, Roulston JE.

Dis Markers. 1989 Jan-Mar;7(1):61-7.

PMID:
2653700
23.

Different reference intervals for the kinetic assay of angiotensin-converting enzyme.

Roulston JE.

Clin Chem. 1987 Dec;33(12):2324-5. No abstract available.

24.
25.

Why is plasma angiotensin-converting enzyme activity elevated in hyperthyroidism?

Roulston JE, Gold A, Wright M, Walker SW.

J R Soc Med. 1987 Aug;80(8):484-5.

26.

The use of captopril and captopril plus frusemide as antihypertensive agents in non-insulin dependent diabetes.

Matthews DM, Wathen CG, Bell D, Collier A, Roulston JE, Clarke BF, Muir AL.

J Hum Hypertens. 1987 Jun;1(1):19-23.

PMID:
3334054
27.

Relationship between thyroid hormones and angiotensin-converting enzyme.

Gow SM, Roulston JE.

Clin Chem. 1987 Jun;33(6):1103. No abstract available.

PMID:
3036400
28.

Effect of the partial beta-agonist prenalterol on plasma renin activity in patients with left ventricular failure.

Wathen CG, Mackay IG, Glover DR, Roulston JE.

Clin Chim Acta. 1987 Jan 15;162(1):97-100.

PMID:
3542308
29.

Use of nifedipine as the drug of third choice in management of hypertension.

Roulston JE, Wathen CG, Muir AL.

Scott Med J. 1986 Oct;31(4):234-8.

PMID:
3563462
31.

Plasma angiotensin-converting enzyme activity in patients with bronchial carcinoma.

Roulston JE, Galloway PJ, Douglas G.

Br J Dis Chest. 1986 Jul;80(3):229-34.

PMID:
3024690
32.

In vitro inhibition of angiotensin-converting enzyme by prednisolone and methylprednisolone.

Roulston JE, Galloway PJ.

Clin Chem. 1986 Apr;32(4):697-8. No abstract available.

33.

An in vitro study of the effects of a beta-blocker and a diuretic upon interconversion of active and inactive renin.

Roulston JE.

Ann Clin Biochem. 1985 Mar;22 ( Pt 2):213-4. No abstract available.

PMID:
3890682
34.

Effects of prednisolone on angiotensin converting enzyme activity.

Roulston JE, O'Malley GI, Douglas JG.

Thorax. 1984 May;39(5):356-60.

35.

The effect of in vitro captopril and angiotensin II on plasma renin activity.

Roulston JE, Wathen CG.

Clin Chim Acta. 1984 Mar 27;138(1):99-103.

PMID:
6370512
36.
37.
38.

Sample collection and processing for the assay of plasma renin activity. A comparison of anticoagulants and inhibitors.

Roulston JE, Wathen CG, Sanger B, Muir AL.

Ann Clin Biochem. 1983 Jul;20 (Pt 4):217-9.

PMID:
6412615
39.

Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker.

MacGregor GA, Banks RA, Markandu ND, Bayliss J, Roulston J.

Br Med J (Clin Res Ed). 1983 May 14;286(6377):1535-8.

40.

Xipamide and cyclopenthiazide in essential hypertension--comparative effects on blood pressure and plasma potassium.

MacGregor GA, Banks RA, Markandu ND, Roulston J.

Br J Clin Pharmacol. 1982 Jun;13(6):859-63.

41.

Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol.

MacGregor GA, Markandu ND, Banks RA, Bayliss J, Roulston JE, Jones JC.

Br Med J (Clin Res Ed). 1982 Mar 6;284(6317):693-6.

42.

Is the renin-angiotensin-aldosterone system involved in the sodium retention in the nephrotic syndrome?

Brown EA, Markandu ND, Roulston JE, Jones BE, Squires M, MacGregor GA.

Nephron. 1982;32(2):102-7.

PMID:
6757778
43.

An increase in a circulating inhibitor of Na+,K+-dependent ATPase: a possible link between salt intake and the development of essential hypertension.

MacGregor GA, Fenton S, Alaghband-Zadeh J, Markandu ND, Roulston JE, de Wardener HE.

Clin Sci (Lond). 1981 Dec;61 Suppl 7:17s-20s.

PMID:
6274566
44.

Evidence for a raised concentration of a circulating sodium transport inhibitor in essential hypertension.

MacGregor GA, Fenton S, Alaghband-Zadeh J, Markandu N, Roulston JE, de Wardener HE.

Br Med J (Clin Res Ed). 1981 Nov 21;283(6303):1355-7.

45.

Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects.

MacGregor GA, Markandu ND, Bayliss J, Roulston JE, Squires M, Morton JJ.

Br Med J (Clin Res Ed). 1981 Aug 8;283(6288):401-3.

46.

Relation between arterial pressure, dietary sodium intake, and renin system in essential hypertension.

Parfrey PS, Markandu ND, Roulston JE, Jones BE, Jones JC, MacGregor GA.

Br Med J (Clin Res Ed). 1981 Jul 11;283(6284):94-7.

47.

Maintenance of blood pressure by the renin-angiotensin system in normal man.

MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ.

Nature. 1981 May 28;291(5813):329-31. No abstract available.

PMID:
7015149
48.

The renin--angiotensin--aldosterone system in the maintenance of blood pressure, aldosterone secretion and sodium balance in normotensive subjects.

MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ.

Clin Sci (Lond). 1980 Dec;59 Suppl 6:95s-99s.

PMID:
7004744
49.

The measurement of angiotensin-converting enzyme in subjects receiving captopril.

Roulston JE, MacGregor GA.

N Engl J Med. 1980 Aug 14;303(7):397. No abstract available.

PMID:
6248782
50.

Does the renin-angiotensin system maintain blood pressure in both hypertensive and normotensive subjects? A comparison of propranolol, saralasin and captopril.

MacGregor GA, Markandu ND, Roulston JE.

Clin Sci (Lond). 1979 Dec;57 Suppl 5:145s-148s. No abstract available.

PMID:
396068

Supplemental Content

Loading ...
Support Center